Precigen, Inc.
PGEN
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.27
Price+5.56%
$0.33
1Y
Price
Market Cap
$2.235b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-4950.0%
EBITDA Margin-5008.3%
Net Profit Margin-1008.1%
Free Cash Flow Margin-4950.0%
EBITDA Margin-5008.3%
Net Profit Margin-1008.1%
Free Cash Flow MarginRevenue
$31.595m
+60.7%
1y CAGR-17.7%
3y CAGR+8.9%
5y CAGREarnings
-$204.418m
-95.6%
1y CAGR-188.6%
3y CAGR-108.8%
5y CAGREPS
-$1.28
-206.4%
1y CAGR-81.7%
3y CAGR-53.8%
5y CAGRBook Value
$20.235m
$138.627m
Assets$118.392m
Liabilities$98.250m
DebtDebt to Assets
70.9%
-0.4x
Debt to EBITDAFree Cash Flow
-$117.568m
+1.5%
1y CAGR-2.8%
3y CAGR-4.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company